ClinicalTrials.gov
public full text
Public Domain
A Study of PLH-2301 in Subjects With Sarcopenia
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia#1378023
- Pleiotropic effects on Sarcopenia subphenotypes point to potential molecular markers for the disease.#1092337
- Prevalence of Sarcopenia in Geriatric Patients#1409150
- Effect of Integrated Care Involving Peripheral Functional Magnetic Stimulation for Sarcopenia#881567
- Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients#1045961
Record · ID 1484551
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive